Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer

American Journal of Clinical Pathology

Volumn 107, Issue 2, 1997, Pages 211-218

  Honkoop, Aafke H ^a   Pinedo, Herbert M ^a   De Jong, Johannes S ^a   Verheul, Henk M W ^a   Linn, Sabine C ^a   Hoekman, Klaas ^a   Wagstaff, John ^a   Van Diest, Paul J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; locally advanced; Neoadjuvant chemotherapy; Tumor biology; Tumor morphology

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CELL ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKERATIN; DNA; DOXORUBICIN; ESTROGEN RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MEMBRANE ANTIGEN; VIMENTIN;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL ULTRASTRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MASTECTOMY; MITOSIS; PLOIDY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031036948     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/107.2.211     Document Type: Article

References (35)

1. Hortogagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer. 1994;23:416-423.
2. Bonadonna G, Veronesi V, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumours with diameters of three centimetres or more. J Natl Cancer Inst. 1990;82:1539-1545.
3. Daidone MG, Silvestrini R, Valentinis B, Ferrari L, Bartoli C. Changes in cell kinetics induced by primary chemotherapy in breast cancer. Int J Cancer. 1991;47:380-383.
4. O'Reilly SM, Camplejohn RS, Rubens RD, Richards MA. DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur J Cancer. 1992;28:681-683.
5. Skoog L, Rutqvist LE, Wilking N. Analysis of hormone receptors and proliferation fraction in fine-needle aspirates from primary breast carcinomas during chemotherapy or tamoxifen treatment. Acta Oncol. 1992;31:139-141.
6. Kennedy S, Merino MJ, Swain SM, Lippman ME. The effects of hormonal and chemotherapy on tumoral and nonneoplastic breast tissue. Hum Pathol. 1990;21:192-198.
7. Briffod M, Spyratos F, Tubiana-Hulin M, et al. Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. Cancer. 1993;63:631-637.
8. Frierson HF, Fechner RE. Histologic grade of locally advanced infiltrating ductal carcinoma after treatment with induction chemotherapy. Am J Clin Pathol. 1994;102:154-157.
9. Rasbridge SA, Gillett CE, Seymour AM, et al. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer. 1994;70:335-341.
10. Pinedo HM, Honkoop AH, Hoekman K, et al. Improved disease-free survival (DFS) of patients with locally advanced breast cancer (LABC) using prolonged dose-intensive neoadjuvant doxorubicin and cyclophosphamide and GM-CSF. Proc Am Soc Clin Oncol. 1996;15:106. Abstract 88.
11. Honkoop AH, Hoekman K, Wagstaff J, et al. Continuous infusion or subcutaneous injection of granulocyte-macrophage colony stimulating factor: increased efficacy and reduced toxicity when given subcutaneously. Br J Cancer. 1996;74:1132-1136.
12. Hoekman K, Wagstaff J, van Groeningen CJ, et al. Effects of recombinant human granulocyte macrophage colony stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer. J Natl Cancer Inst. 1991;83:1546-1553.
13. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem. 1983;31:1333-1335.
14. van Diest PJ, Baak JPA. The morphometric prognostic index is the strongest prognosticator in premenopausal lymph node negative and lymph node positive breast cancer patients. Hum Pathol. 1991;22:326-330.
15. van Diest PJ, Baak JPA, Matze-Cok P, et al. Reproducibility of mitosis counting in 2469 breast cancer specimens: results from the multicenter Morphometric Mammary Carcinoma Project. Hum Pathol. 1992;23: 603-607.
16. Fleege JC, van Diest PJ, Baak JPA. Computer assisted efficiency testing of different sampling methods for selective nuclear graphic tablet morphometry. Lab Invest. 1990;63:270-275.
17. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991;39:741-748.
18. Bosman FT, De Goeij AFPM, Rousch M. Quality control in immunocytochemistry: experiences with the oestrogen receptor assay. J Clin Pathol. 1992;45:120-124.
19. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new, significant, and independent prognostic indicator in early staged breast carcinoma. J Natl Cancer Inst. 1992;84: 1875-1887.
20. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
21. Chevillard S, Pouillart P, Beldjord C, et al. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer. 1996;77:292-300.
22. Masters JRW, Camplejohn RS, Millis RR, Rubens RD. Histological grade, elastosis, DNA ploidy and the response to chemotherapy of breast cancer. Br J Cancer. 1987;55:455-457.
23. Iozzo RV. Tumor stroma as a regulator of neoplastic behavior. Lab Invest. 1995;73:157-160.
24. Vaage J. Fibrosis in immune control of mammary tumor growth. Int J Cancer. 1992;51:325-328.
25. Folkman J. Tumor angiogenesis. In: Holland J, Frei E III, Bast RC, et al, eds. Cancer Medicine. Melbourne, Pa: 1993;153-170.
26. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267: 10931-10934.
27. Brem SS, Gullino PM, Medina D. Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science. 1977;195:880-882.
28. Bosari S, Lee AKC, DeLellis RA, et al. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol. 1992;23:755-761.
29. Toi M, Kashitani J, Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer. 1993;55:371-374.
30. Gasparini G, Weidner N, Bevilacqua P, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol. 1994;12:454-466.
31. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet. 1992;340:1120-1124.
32. Fox SB, Leek RD, Smith K, et al. Tumor angiogenesis in node-negative breast carcinomas: relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat. 1994;29:109-116.
33. Steiner R. Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay. In: Steiner R, Weisz PB, Langer R, eds. Angiogenesis: Key Principles - Science, Technology, Medicine. Basel, Switzerland: Birkhauser Verlaga; 1992:449-154.
34. Bussolino F, Colotta F, Bocchietto E, Guglielmetti A, Mantovani A. Recent developments in the cell biology of granulocyte-macrophage colony-stimulating factor: activities on endothelial cells. Int J Clin Lab Res. 1993;23:8-12.
35. Feder LS, Laskin DL. Regulation of hepatic endothelial cell and macrophage proliferation and nitric oxide production by GM-CSF, M-CSF, and IL-1b following acute endotoxemia. J Leukoc Biol. 1994;55:507-513.